Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more
Cynata Therapeutics Limited (CYYNF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.969x
Based on the latest financial reports, Cynata Therapeutics Limited (CYYNF) has a cash flow conversion efficiency ratio of -0.969x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.79 Million) by net assets ($5.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cynata Therapeutics Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Cynata Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cynata Therapeutics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cynata Therapeutics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Crown Crafts Inc
NASDAQ:CRWS
|
-0.022x |
|
Truong Thanh Energy and Real Estate JSC
VN:TEG
|
N/A |
|
Globon Co. Ltd
KQ:019660
|
-0.091x |
|
NHOA S.A
PINK:ENGPF
|
-0.029x |
|
Echomarketing Co.Ltd
KQ:230360
|
0.049x |
|
WEBSTEP ASA NK 1
F:5ZF
|
N/A |
|
Redefine Properties Ltd
JSE:RDF
|
0.029x |
|
Infrea AB
ST:INFREA
|
0.077x |
Annual Cash Flow Conversion Efficiency for Cynata Therapeutics Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Cynata Therapeutics Limited from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $5.98 Million | $-8.72 Million | -1.458x | -5.63% |
| 2024-06-30 | $7.22 Million | $-9.96 Million | -1.380x | -61.69% |
| 2023-06-30 | $16.73 Million | $-14.28 Million | -0.854x | -520.04% |
| 2022-06-30 | $23.96 Million | $-3.30 Million | -0.138x | +24.35% |
| 2021-06-30 | $28.37 Million | $-5.16 Million | -0.182x | +9.81% |
| 2020-06-30 | $16.79 Million | $-3.39 Million | -0.202x | +67.25% |
| 2019-06-30 | $10.97 Million | $-6.76 Million | -0.616x | -133.37% |
| 2018-06-30 | $15.39 Million | $-4.06 Million | -0.264x | +9.59% |
| 2017-06-30 | $13.86 Million | $-4.05 Million | -0.292x | +42.07% |
| 2016-06-30 | $8.58 Million | $-4.33 Million | -0.504x | -69.48% |
| 2015-06-30 | $8.75 Million | $-2.60 Million | -0.297x | -58.11% |
| 2014-06-30 | $9.85 Million | $-1.85 Million | -0.188x | +59.64% |
| 2013-06-30 | $1.64 Million | $-765.76K | -0.466x | -- |